

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10565900	
	Filing Date		2006-01-24	
	First Named Inventor	Bridon et al.		
	Art Unit	1654		
	Examiner Name	Christina Bradley		
Attorney Docket Number		C2077-7016US		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	1570532	GB		1980-07-02	Dainippon Pharmaceutical Co. LTD.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

Receipt date: 05/24/2010

Application Number	10565900	10565900 - GAU: 1654
Filing Date	2006-01-24	
First Named Inventor	Bridon et al.	
Art Unit	1654	
Examiner Name	Christina Bradley	
Attorney Docket Number	C2077-7016US	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

1	Notice of Opposition for European Patent Application No. 04801809.7 dated 04-29-2010.	<input type="checkbox"/>
2	CHUANG, et al. (May 2002) "Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin", Pharmaceutical Research, vol. 19(5), 569-577.	<input type="checkbox"/>
3	KITIGAWA et al., (1976) "Enzyme Coupled Immunoassay of Insulin Using a Novel Coupling Reagent" J. Biochem., vol. 79, p. 233-236.	<input type="checkbox"/>
4	SCHROER et al., (August 1979) "H-2-Linked Ir Gene Control of Antibody Responses to Insulin", The Journal of Immunology, vol. 123(2) p. 670-675.	<input type="checkbox"/>
5	SHECHTER et al., (May 1978) "Fluorescent labeling of hormone receptors in viable cells: Preparation and properties of highly fluorescent derivatives of epidermal growth factor and insulin", Proc. Natl. Acad. Sci. vol 75(5). 2135-2139.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Christina Bradley/	Date Considered	02/15/2011
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.